Drugs / INO-3401
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01405885 | May 2011 → Aug 2013 | — | Inovio Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01403155 | May 2011 → Aug 2012 | — | Inovio Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INO-3401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403155 ↗ |
| Modality | Vaccine | “The investigators have developed a DNA vaccine, INO-3401, which includes plasmids targeting the proteins of the H5N1 avian influenza virus.” NCT01403155 ↗ |